IRIDEX Reports Record 2012 Fourth Quarter Results Board Approves New $3.0 Million Stock Repurchase Program PR Newswire MOUNTAIN VIEW, Calif., Feb. 28, 2013 MOUNTAIN VIEW, Calif., Feb. 28, 2013 /PRNewswire/ --IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter ended December 29, 2012. oOphthalmology revenues in the fourth quarter were $9.2 million, compared to $8.6 million in the prior year period and $7.9 million in the 2012 third quarter. The fourth quarter results were a record high for ophthalmology sales in a quarter. oGross margin for the fourth quarter was 47.0%, compared to 49.6% in both the prior year period and the 2012 third quarter. Margins were impacted in the quarter by a shift in product mix towards the sale of laser systems – including a greater-than-expected response to promotional pricing during a key trade show during the period. oOperating expenses were $4.0 million in the fourth quarter compared to $3.1 million in the prior year period, which included a one-time credit for a legal settlement of $1.3 million; and $4.5 million in the 2012 third quarter, which included one-time severance expenses of approximately $0.7 million. oIncome from continuing operations for the fourth quarter was $0.3 million or $0.03 per diluted share, compared with income from continuing operations of $0.8 million, or $0.08 per diluted share, in the prior year period. oGuidance for first quarter 2013: The Company expects to achieve revenues between $8.7 million and $9.0 million and gross margins between 47% and 49%. Operating expenses are expected to be between $3.8 million and $4.0 million. Additionally, the Company received $0.5 million in the form of a cash distribution from an insurance carrier which will be recorded in the first quarter. CEO William M. Moore said, "We have implemented a number of changes to the organization flattening the management structure and making the focus more customer-centric and market driven with an eye to profitability. We are now investing in products that our customers want, that can be delivered to the market in a reasonable amount of time and that are aligned with growing clinical trends in ophthalmology. And we are making these changes in the framework of fiscal controls and a focus on generating cash and enhancing shareholder value." Moore continued, "Going forward, we will look to grow and increase profitability, we will be opportunistic in acquiring or partnering with ophthalmic companies that have developed excellent technologies and we will continue to deploy cash from our strong balance sheet and profitable operations to directly benefit our shareholders through our share buyback program. For the last two years we had committed up to $4.0 million to our stock repurchase program which ended this February. Today, the Board approved a new one year $3.0 million stock repurchase program that replaces our prior two year $4.0 million program." The preceding commentary relates to the results of the Company's continuing ophthalmology business. In February 2012, the Company sold its aesthetics laser business and the financial statements reflect the results of its aesthetics laser business as discontinued operations. Fourth Quarter Business Highlights oThe Company completed a tender offer that resulted in the repurchase of an aggregate of 487,500 shares of its common stock at a purchase price of $4.10 per share, for a total cost of approximately $2.0 million. Those shares represented approximately 5.5 percent of IRIDEX's then issued and outstanding shares of common stock. oThe Company announced FDA 510(k) and CE clearance of the TxCell™ Scanning Laser Delivery System. This new product saves significant time in a variety of laser photocoagulation procedures by allowing physicians to deliver the laser in a multi-spot scanning mode, a more efficient method for these procedures than the traditional single spot mode. Management believes that the clinical and practice benefits of this technology will accelerate the adoption of IRIDEX' proprietary MicroPulse™ technology as it applies to several clinical procedures. Conference Call IRIDEX management will conduct a conference call later today, Thursday, February 28, 2013 at 5:00 p.m. Eastern Time. Interested parties may access the live conference call via telephone by dialing (866) 225-8754 (U.S.) or (480) 629-9818 (International) and quoting Conference ID 4603021, or by visiting the Company's website at www.iridex.com. A telephone replay will be available beginning on Thursday, February 28, 2013 through Thursday, March 7, 2013 by dialing (800) 406-7325 (U.S.) or (303) 590-3030 (International) and entering Access Code 4603021. In addition, later today an archived version of the webcast will be available on the Company's website at www.iridex.com. About IRIDEX IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the Company's website at http://www.iridex.com/. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the size and growth of and trends in the markets in which the Company operates, the success of the Company's development, marketing and sales efforts, MicroPulse laser therapy, the Company's growth strategy, the Company's acquisition strategy, sales revenue growth, operational plans, profitability, the Company's projected fiscal 2013 financial results and the Company's share repurchase program. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2012, June 30, 2012 and September 29, 2012 which were filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated. TABLES FOLLOW IRIDEX Corporation Condensed Consolidated Statements of Operations (In thousands, except per share data) (unaudited) Three Months Ended Twelve Months Ended December 29, December 31, December 29, December 31, 2012 2011 2012 2011 Total revenues $ 9,228 $ 8,620 $ 33,859 $ 33,159 Cost of revenues 4,890 4,342 17,513 16,869 Gross profit 4,338 4,278 16,346 16,290 Operating expenses: Research and 1,091 1,166 4,385 3,913 development Sales and marketing 2,034 2,147 7,895 7,458 General and 908 1,066 4,926 4,259 administrative Legal settlement, net - (1,274) - (1,274) of expenses Total operating 4,033 3,105 17,206 14,356 expenses Income (loss) from 305 1,173 (860) 1,934 operations Legal settlement - - 800 800 Other expense, net (18) (250) (210) (296) Income (loss) from continuing operations 287 923 (270) 2,438 before income taxes Provision for (benefit 34 122 (100) 297 from) income taxes Income (loss) from 253 801 (170) 2,141 continuing operations Income (loss) from discontinued 149 (15) (264) 469 operations, net of tax (Loss) gain on sale of discontinued (160) - 1,872 - operations, net of tax (Loss) income from discontinued (11) (15) 1,608 469 operations, net of tax Net income $ $ $ $ 242 786 1,438 2,610 Net (loss) income per share: Basic: Continuing operations $0.03 $0.09 ($0.02) $0.24 Discontinued ($0.00) ($0.00) $0.18 $0.05 operations $0.03 $0.09 $0.16 $0.29 Diluted: Continuing operations $0.03 $0.08 ($0.02) $0.21 Discontinued ($0.01) ($0.00) $0.18 $0.05 operations $0.02 $0.08 $0.16 $0.26 Weighted average shares used in computing net income per share Basic 8,820 8,945 8,935 8,958 Diluted 10,071 10,200 8,935 10,225 IRIDEX Corporation Condensed Consolidated Balance Sheets (In thousands) (unaudited) December 29, December 31, 2012 2011 Assets Current Assets: Cash and cash equivalents $ 11,901 $ 10,789 Accounts receivable, net 5,480 5,551 Inventories, net 8,035 6,659 Prepaids and other current assets 1,129 464 Current assets of discontinued operations 510 6,043 Total current assets 27,055 29,506 Property and equipment, net 483 325 Other long-term assets 287 199 Other intangible assets, net 554 745 Goodwill 533 533 Non-current assets of discontinued operations - 841 Total assets $ 28,912 $ 32,149 Liabilities and Stockholders' Equity Current Liabilities: Accounts payable $ 2,105 $ 1,580 Accrued compensation 1,563 1,180 Accrued expenses 1,242 1,920 Accrued warranty 453 556 Deferred revenue 1,004 1,014 Current liabilities of discontinued operations - 2,663 Total current liabilities 6,367 8,913 Long Term Liabilities: Other long-term liabilities 640 810 Total liabilities 7,007 9,723 Stockholders' Equity: Convertible preferred stock 5 5 Common stock 94 92 Additional paid-in capital 38,958 42,032 Accumulated other comprehensive loss - (35) Treasury stock, at cost - (1,078) Accumulated deficit (17,152) (18,590) Total stockholders' equity 21,905 22,426 Total liabilities and stockholders' equity $ 28,912 $ 32,149 SOURCE IRIDEX Corporation Website: http://www.iridex.com Contact: Company, Jim Mackaness, CFO & COO, +1-650-940-4700; or Investor Relations, Matt Clawson for Allen & Caron, +1-949-474-4300, firstname.lastname@example.org
IRIDEX Reports Record 2012 Fourth Quarter Results
Press spacebar to pause and continue. Press esc to stop.